Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

NCT03150160 PHASE4 COMPLETED Results posted

The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from further IOP lowering.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE4
Status	COMPLETED
Enrolment	1
Start date	Thu Sep 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Glaucoma

Interventions

• brinzolamide 1%/brimonidine 0.2% fixed combination
• Placebo
• travoprost 0.004% ophthalmic solution

Countries

South Korea